DX-88 and HAE: a developmental perspective.

Abstract	An example of an approach to the developmental philosophy of novel recombinant products is explored by using the exemplar of Hereditary Angioedema (HAE). Plasma kallikrein is believed to be an important mediator of angioedema in patients with genetic deficiency of C1 esterase inhibitor (HAE patients). DX-88, a novel Kunitz domain produced by phage display (a powerful method of generating novel binders to potentially therapeutic targets), is a potent and selective inhibitor of plasma kallikrein which in early clinical studies demonstrates a useful efficacy/safety ratio in the treatment of acute attacks of HAE.
Authors	Anthony Williams, Lynn G Baird
Journal	Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (Transfus Apher Sci) Vol. 29 Issue 3 Pg. 255-8 (Dec 2003) ISSN: 1473-0502 [Print] England
PMID	14572818 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Complement C1 Inactivator Proteins Peptide Library Recombinant Proteins Kallikreins
Topics	Acute Disease Angioedema (drug therapy) Clinical Trials as Topic Complement C1 Inactivator Proteins (therapeutic use) Female Humans Kallikreins (antagonists & inhibitors, blood) Male Peptide Library Protein Structure, Tertiary Recombinant Proteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!